

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/779,447	02/09/2001	Dipak K. Banerjee	P19850.p06	6690
7055 7	7590 01/13/2005		EXAMINER	
GREENBLUM & BERNSTEIN, P.L.C. 1950 ROLAND CLARKE PLACE			OWENS JR, HOWARD V	
RESTON, VA 20191			ART UNIT	PAPER NUMBER
·			1623	
			DATE MAILED: 01/13/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Applicati n No.	Applicant(s)				
Advisory Action	09/779,447	BANERJEE ET AL.				
navioury notion	Examiner	Art Unit				
	Howard V Owens	1623				
The MAILING DATE of this communication appears on the cover sheet with the correspondenc address						
THE REPLY FILED 10/26/2004 FAILS TO PLACE THIS Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment whicl	ation. A proper reply to a				
PERIOD FOR RE	EPLY [check either a) or b)]					
a) The period for reply expires <u>6</u> months from the mailing date						
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of 1 (2) as set forth in (b) above, if checked. Any reply received by the Officitimely filed, may reduce any earned patent term adjustment. See 37 C	ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THe date on which the petition under 37 CFI fextension and the corresponding amount the shortened statutory period for reply the later than three months after the mail	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension unt of the fee. The appropriate extension originally set in the final Office action; or				
1. A Notice of Appeal was filed on 20 September 2004. Appellant's Brief must be filed within the period set forth in 37 CFR 1:192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered be	ecause:					
(a) They raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) ☐ they are not deemed to place the application ir issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the				
(d) they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE:						
3. Applicant's reply has overcome the following reject	ion(s):					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:	reconsideration has been consideration	dered but does NOT place the				
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly				
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected: 9,14 and 18.						
Claim(s) withdrawn from consideration:						
8. The drawing correction filed on is a) appr	oved or b) disapproved by the	ne Examiner.				
9. Note the attached Information Disclosure Statemen	•—					
10. Other:		PERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1908				
		/				

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03)



Application No.

The examiner maintains the position that the prior art of record provides sufficient and reasonable motivation to establish the use of Tunicamycin for the inhibition of angiogenesis. Applicant derives the in vivo correlation from the same in vitro data present in the prior art of record; moreover, the in vitro data presented in the prior art of record presents a reasonable model for the treatment of the specific condition that applicant is targeting.